Biomarkers for the diagnosis and management of Parkinson's disease.
Biomarkers for the diagnosis and management of Parkinson's disease.
复制标题
DOI：
10.1517/17530059.2013.733694
复制
发表时间：
2013-01-01
期刊：
影响因子：
--
通讯作者：
Hashimoto, Makoto
中科院分区：
文献类型：
--
作者：
Waragai, Masaaki;Sekiyama, Kazunari;Hashimoto, Makoto
简介：帕金森病（PD）是最常见的导致运动障碍的神经退行性疾病，其神经病理学特征是多巴胺能神经元的进行性丧失，细胞内α -突触核蛋白沉积和路易小体的形成。与帕金森病相关的其他神经退行性疾病相比，帕金森病本身的明确诊断困难是临床帕金森病研究的中心问题。然而，包括成像技术、基因检测和生物标记物测量在内的诊断方法的最新进展可能允许早期诊断，从而潜在地改善PD的管理。涵盖领域：除了临床症状和成像技术，从体液（如脑脊液）中获得的一些遗传和生物标记物可能对PD的早期检测有希望。通常很难做出准确的诊断，并将PD与其他具有帕金森病特征的疾病区分开来，特别是在疾病的早期阶段。在这方面，PD特异性的生物标志物，结合临床症状的观察，可能有助于PD的早期诊断和改善治疗。专家意见：良好的PD生物标志物可能有助于早期诊断、管理和跟踪疾病进展。此外，使用几种生物标志物的联合分析可能允许检测临床前PD，这反过来可能有助于使用疾病修饰药物预防疾病发作。
INTRODUCTION: Parkinson's disease (PD) is the most common neurodegenerative disease leading to movement disorders, and is characterized neuropathologically by the progressive loss of dopaminergic neurons, intracellular alpha-synuclein deposition and the formation of Lewy bodies. The difficulty of making a definitive diagnosis of PD itself, as opposed to other neurodegenerative diseases associated with parkinsonism, is a central issue in clinical PD research. However, recent advances in diagnostic methods, encompassing imaging techniques, genetic testing and measurement of biological markers may permit earlier diagnosis, and thus potentially improved management of PD.AREAS COVERED: In addition to clinical symptoms and imaging techniques, a number of genetic and biological markers obtained from body fluids such as cerebrospinal fluids may hold promise for the early detection of PD. It is often difficult to make an accurate diagnosis and to distinguish PD from other diseases with features of parkinsonism, particularly during the early stages of the disease. In this regard, biomarkers which are specific for PD, in combination with observation of clinical symptoms, may facilitate the early diagnosis and improved management of PD.EXPERT OPINION: Good biomarkers for PD could be helpful for early diagnosis, management and tracking of disease progression. Furthermore, combined analysis using several kinds of biomarkers may allow the detection of preclinical PD, which in turn may facilitate a prevention of disease onset with the use of disease-modifying drugs.